News Article

British multinational biopharmaceutical company GSK has reached a definitive agreement to acquire 35Pharma, a Canada-based clinical-stage biopharmaceutical company, for a total cash consideration of $950 million.

The deal centres on 35Pharma’s lead asset, HS235, which is a potential best-in-class protein-based therapeutic designed to treat cardiopulmonary diseases. This investigational medicine has successfully completed phase I trials in healthy volunteers and is prepared for imminent phase II studies.

For investors and healthcare operators, the acquisition represents a strategic expansion of GSK’s respiratory and immunology portfolio into the high-growth pulmonary hypertension market.

Tony Wood, Chief Scientific Officer, GSK, said: “Pulmonary hypertension affects millions of people worldwide, yet patients are underserved. We’re delighted to add HS235 to our pipeline, a potential best-in-class medicine with a differentiated profile to reduce risk of bleeding and provide potential metabolic benefits clinically relevant to PH patients.

“HS235’s potential protective effects on vascular function, alongside potential benefits on fat-derived markers of metabolism and inflammation, also offer new development opportunities within our RI&I portfolio to achieve broader coverage across the metabolic, inflammatory, vascular and fibrotic drivers of multiple chronic diseases that affect the lung, liver and kidney.”

The deal is currently subject to customary closing conditions and regulatory clearances.